 Xenon Pharmaceuticals Inc NASDAQ: XENE is trading significantly higher Monday after the company announced its phase 2 study of XEN1101 for the treatment of epilepsy met all primary and secondary endpoints. XEN1101 demonstrated a statistically significant and dose-dependent reduction from baseline in monthly focal seizure frequency when compared to the placebo. 